225Ac-Satoreotide, developed by Ariceum Therapeutics, represents a groundbreaking advancement in the treatment of extensive stage small cell lung cancer (SCLC) and other SSTR2-positive tumours. This first-in-class somatostatin receptor 2 antagonist has shown a superior pharmacokinetic profile and higher pre-clinical anti-tumour efficacy compared to DOTA-TATE, regardless of the radionuclide used.
At the European Association of Nuclear Medicine (EANM) Annual Conference in Hamburg, Germany, Ariceum Therapeutics presented data highlighting the anti-tumour efficacy of 225Ac-Satoreotide. The study compared the effects of different radiolabelled satoreotide antagonists against DOTA-TATE agonists in mice with SSTR2 positive xenografts of SCLC and pancreatic cancer. Results indicated that 225Ac-satoreotide exhibited the strongest anti-tumoural effect at a low single dose, with 100% survival observed in mice treated with a single dose of 30 kBq 225Ac-satoreotide.
Manfred Rüdiger, CEO of Ariceum Therapeutics, emphasized the potential of satoreotide to clinically outperform SSTR2 targeting agonists, citing its significant efficacy in tumour growth control and complete tumour eradication in some cases. The findings support the further clinical development of satoreotide for treating SCLC, Merkel Cell Carcinoma (MCC), and other cancers.
The presentation, titled '225Ac-SSO110 induces long-lasting anti-tumour responses in contrast to 225Ac-DOTA-TATE and 161Tb-DOTA-TATE in the treatment of SSTR2-positive tumour xenografts,' was delivered by Prachi Desai, a scientist at Ariceum Therapeutics. The study's results are a testament to the potential of 225Ac-Satoreotide in revolutionizing cancer treatment, offering hope for patients with hard-to-treat cancers.
